Kelly C. Goldsmith, MD
-
Research Program
-
Phone Number
-
Email Address
Kelly Goldsmith, MD, is a professor in the Department of Pediatrics at Emory University School of Medicine. Dr. Goldsmith serves as co-leader of the Discovery and Developmental Therapeutics Research Program at Winship Cancer Institute of Emory University, as director Neuroblastoma/MIBG Therapy Program and as clinical director, Aflac Precision Medicine Program at the Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta. She is board certified in Pediatric Hematology and Oncology by the American Board of Pediatrics, and specializes in the treatment of neuroblastoma, Wilms tumor and other renal tumors of childhood.
Dr. Goldsmith received her Medical Degree from the University of Alabama School of Medicine in Birmingham, Alabama. She completed a residency in pediatrics and a fellowship in pediatric hematology and oncology at The Children's Hospital of Philadelphia in Philadelphia, Pennsylvania.
Dr. Goldsmith holds professional memberships with several scientific societies including American Society of Pediatric Hematology and Oncology, American Association for Cancer Research, American Society of Clinical Oncology, and Children's Oncology Group.
Dr. Goldsmith's laboratory investigates the molecular mechanisms of chemotherapy resistance in pediatric neuroblastoma, focusing on experimental therapeutics that restore therapy sensitivity. Her research expertise is in apoptosis deregulation in cancer, the Bcl-2 family, and neurodevelopmental genes that play a role in therapy resistance. Her translational research provided the concept behind a first in pediatrics Phase I trial of simvastatin in combination with chemotherapy for recurrent solid/CNS tumors of childhood. She is co-chair of a NANT Precision Medicine Study for recurrent neuroblastoma and chair of the AflacST1402 trial. Dr. Goldsmith rounds out her bench to bedside personality as the clinical director of our Refractory and Recurrent Neuroblastoma Program where she and her team work to match a relapsed patient with the appropriate therapy for their recurrent disease.
|
|
|
|
|
|
|
|
|
Grant Number | Title |
---|---|
1R01CA248501-01A1 | Mechanistic biomarkers to enable Bcl2 inhibitor therapies for neuroblastoma |
Title/Journal | Authors | Publication Date |
---|---|---|
Pediatric blood & cancer |
J Dhuse, T Cash, MS Elges, A Alazraki, R Beer, A Jergel, KC Goldsmith, M Hall, PP Kamat | 10/01/2024 |
Current and Emerging Biomarkers: Impact on Risk Stratification for Neuroblastoma. Journal of the National Comprehensive Cancer Network : JNCCN |
MS Irwin, KC Goldsmith | 08/01/2024 |
Communications biology |
K Mittal, GW Cooper, BP Lee, Y Su, KT Skinner, J Shim, HC Jonus, WJ Kim, M Doshi, D Almanza, BD Kynnap, AL Christie, X Yang, GS Cowley, BA Leeper, CL Morton, B Dwivedi, T Lawrence, M Rupji, P Keskula, S Meyer, CM Clinton, M Bhasin, BD Crompton, YY Tseng, JS Boehm, KL Ligon, DE Root, AJ Murphy, DM Weinstock, PC Gokhale, JM Spangle, MN Rivera, EA Mullen, K Stegmaier, KC Goldsmith, WC Hahn, AL Hong | 04/08/2024 |
Children's Oncology Group's 2023 blueprint for research: Neuroblastoma. Pediatric blood & cancer |
R Bagatell, SG DuBois, A Naranjo, J Belle, KC Goldsmith, JR Park, MS Irwin | 09/01/2023 |
Pediatric blood & cancer |
T Cash, HC Jonus, M Tsvetkova, JH Beumer, A Sadanand, JY Lee, CJ Henry, D Aguilera, RD Harvey, KC Goldsmith | 08/01/2023 |
Cell reports. Medicine |
JY Lee, HC Jonus, A Sadanand, GM Branella, V Maximov, S Suttapitugsakul, MJ Schniederjan, J Shim, A Ho, KK Parwani, A Fedanov, AA Pilgrim, JA Silva, RW Schnepp, CB Doering, R Wu, HT Spencer, KC Goldsmith | 06/20/2023 |
Nature communications |
ER Berko, GM Witek, S Matkar, ZO Petrova, MA Wu, CM Smith, A Daniels, J Kalna, A Kennedy, I Gostuski, C Casey, K Krytska, M Gerelus, D Pavlick, S Ghazarian, JR Park, A Marachelian, JM Maris, KC Goldsmith, R Radhakrishnan, MA Lemmon, YP Mossé | 05/05/2023 |
Nature medicine |
KC Goldsmith, JR Park, K Kayser, J Malvar, YY Chi, SG Groshen, JG Villablanca, K Krytska, LM Lai, PT Acharya, F Goodarzian, B Pawel, H Shimada, S Ghazarian, L States, L Marshall, L Chesler, M Granger, AV Desai, R Mody, DA Morgenstern, S Shusterman, ME Macy, N Pinto, G Schleiermacher, K Vo, HC Thurm, J Chen, M Liyanage, G Peltz, KK Matthay, ER Berko, JM Maris, A Marachelian, YP Mossé | 05/01/2023 |
Case reports in oncology |
SG Mitchell, GD Basu, B Eaton, LJ Goodman, KC Goldsmith | 01/01/2023 |
Oncoimmunology |
AA Pilgrim, HC Jonus, A Ho, AC Cole, J Shim, KC Goldsmith | 01/01/2023 |
Advanced science (Weinheim, Baden-Wurttemberg, Germany) |
L Ning, J Shim, ML Tomov, R Liu, R Mehta, A Mingee, B Hwang, L Jin, A Mantalaris, C Xu, M Mahmoudi, KC Goldsmith, V Serpooshan | 08/01/2022 |
Reduced ER-mitochondria connectivity promotes neuroblastoma multidrug resistance. The EMBO journal |
J Çoku, DM Booth, J Skoda, MC Pedrotty, J Vogel, K Liu, A Vu, EL Carpenter, JC Ye, MA Chen, P Dunbar, E Scadden, TD Yun, E Nakamaru-Ogiso, E Area-Gomez, Y Li, KC Goldsmith, CP Reynolds, G Hajnoczky, MD Hogarty | 04/19/2022 |
JCO precision oncology |
RJ Summers, SM Castellino, CC Porter, TJ MacDonald, GD Basu, S Szelinger, MK Bhasin, T Cash, AB Carter, RC Castellino, JR Fangusaro, SG Mitchell, MG Pauly, B Pencheva, DS Wechsler, DK Graham, KC Goldsmith | 04/01/2022 |
Oncoimmunology |
HC Jonus, RE Burnham, A Ho, AA Pilgrim, J Shim, CB Doering, HT Spencer, KC Goldsmith | 01/01/2022 |
Journal of clinical oncology : official journal of the American Society of Clinical Oncology |
SG DuBois, MM Granger, S Groshen, D Tsao-Wei, L Ji, A Shamirian, S Czarnecki, F Goodarzian, R Berkovich, H Shimada, JG Villablanca, KT Vo, N Pinto, YP Mosse, JM Maris, S Shusterman, SL Cohn, KC Goldsmith, B Weiss, GA Yanik, CJ Twist, MS Irwin, DA Haas-Kogan, JR Park, A Marachelian, KK Matthay | 11/01/2021 |
A New Player in Neuroblastoma: YAP and Its Role in the Neuroblastoma Microenvironment. Cancers |
J Shim, KC Goldsmith | 09/16/2021 |
Molecular cancer therapeutics |
L Vernooij, LT Bate-Eya, LK Alles, JY Lee, B Koopmans, HC Jonus, NA Schubert, L Schild, D Lelieveld, DA Egan, M Kerstjens, RW Stam, J Koster, KC Goldsmith, JJ Molenaar, MEM Dolman | 06/01/2021 |
Cancer research |
J Shim, JY Lee, HC Jonus, A Arnold, RW Schnepp, KM Janssen, V Maximov, KC Goldsmith | 11/01/2020 |
Pediatric blood & cancer |
M Qayed, T Cash, M Tighiouart, TJ MacDonald, KC Goldsmith, R Tanos, L Kean, B Watkins, Y Suessmuth, C Wetmore, HM Katzenstein | 04/01/2020 |
Clinical genitourinary cancer |
JT Brown, LR Harik, MS Barbee, N Esiashvili, ML Badell, KC Goldsmith, VA Master, MA Bilen | 02/01/2020 |
Pediatric blood & cancer |
AJ Esbenshade, LS Kahalley, R Baertschiger, R Dasgupta, KC Goldsmith, PC Nathan, P Harker-Murray, CL Kitko, EA Kolb, ES Murphy, JA Muscal, CR Pierson, D Reed, R Schore, Y Unguru, R Venkatramani, B Wistinghausen, G Dhall | 10/01/2019 |
Tumour-associated macrophages exhibit anti-tumoural properties in Sonic Hedgehog medulloblastoma. Nature communications |
V Maximov, Z Chen, Y Wei, MH Robinson, CJ Herting, NS Shanmugam, VA Rudneva, KC Goldsmith, TJ MacDonald, PA Northcott, D Hambardzumyan, AM Kenney | 06/03/2019 |
Oncoimmunology |
JT Zoine, KA Knight, LC Fleischer, KS Sutton, KC Goldsmith, CB Doering, HT Spencer | 01/01/2019 |
Clinical cancer research : an official journal of the American Association for Cancer Research |
SG DuBois, YP Mosse, E Fox, RA Kudgus, JM Reid, R McGovern, S Groshen, R Bagatell, JM Maris, CJ Twist, K Goldsmith, MM Granger, B Weiss, JR Park, ME Macy, SL Cohn, G Yanik, LM Wagner, R Hawkins, J Courtier, H Lai, F Goodarzian, H Shimada, N Boucher, S Czarnecki, C Luo, D Tsao-Wei, KK Matthay, A Marachelian | 12/15/2018 |
Future oncology (London, England) |
AE Place, K Goldsmith, JP Bourquin, ML Loh, L Gore, DA Morgenstern, Y Sanzgiri, D Hoffman, Y Zhou, JA Ross, B Prine, M Shebley, M McNamee, T Farazi, SY Kim, M Verdugo, L Lash-Fleming, CM Zwaan, J Vormoor | 09/01/2018 |
Transfusion |
DV Runco, CD Josephson, SS Raikar, KC Goldsmith, G Lew, M Pauly, RM Fasano | 05/01/2018 |
Clinical cancer research : an official journal of the American Association for Cancer Research |
A Marachelian, JG Villablanca, CW Liu, B Liu, F Goodarzian, HA Lai, H Shimada, HC Tran, JA Parra, R Gallego, N Bedrossian, S Young, S Czarnecki, R Kennedy, BD Weiss, K Goldsmith, M Granger, KK Matthay, S Groshen, S Asgharzadeh, R Sposto, RC Seeger | 09/15/2017 |
Pediatric blood & cancer |
JL Metts, SI Park, BP Soares, C Fong, JA Biegel, KC Goldsmith | 09/01/2017 |
International journal of radiation oncology, biology, physics |
MJ Ferris, H Danish, JM Switchenko, C Deng, BA George, KC Goldsmith, KJ Wasilewski, WT Cash, MK Khan, BR Eaton, N Esiashvili | 03/15/2017 |
Cancer medicine |
C Wetmore, VM Daryani, CA Billups, JM Boyett, S Leary, R Tanos, KC Goldsmith, CF Stewart, SM Blaney, A Gajjar | 07/01/2016 |
Select Bcl-2 antagonism restores chemotherapy sensitivity in high-risk neuroblastoma. BMC cancer |
R Tanos, D Karmali, S Nalluri, KC Goldsmith | 02/13/2016 |
EGFR signaling defines Mcl⁻1 survival dependency in neuroblastoma. Cancer biology & therapy |
S Nalluri, SK Peirce, R Tanos, HA Abdella, D Karmali, MD Hogarty, KC Goldsmith | 01/01/2015 |
Multiple components of the spliceosome regulate Mcl1 activity in neuroblastoma. Cell death & disease |
TW Laetsch, X Liu, A Vu, M Sliozberg, M Vido, OU Elci, KC Goldsmith, MD Hogarty | 02/20/2014 |
Mitochondrial Bcl-2 family dynamics define therapy response and resistance in neuroblastoma. Cancer research |
KC Goldsmith, M Gross, S Peirce, D Luyindula, X Liu, A Vu, M Sliozberg, R Guo, H Zhao, CP Reynolds, MD Hogarty | 05/15/2012 |